Genmab News

To comply with applicable regulation in Denmark, product-related media releases are removed from our website within three weeks of publication. They are available upon request. Please contact us here.

Jul 4, 2022 at 10:16 AM CEST Transactions in connection with share buy-back program	Download Download
Jul 1, 2022 at 4:15 PM CEST Major Shareholder Announcement	Download
Jun 30, 2022 at 8:25 PM CEST Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)	Download
Jun 27, 2022 at 10:10 AM CEST Transactions in connection with share buy-back program	Download Download
Jun 23, 2022 at 5:55 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Jun 20, 2022 at 4:36 PM CEST Major Shareholder Announcement	Download
Jun 17, 2022 at 4:39 PM CEST Genmab Announces Initiation of Share Buy-Back Program	Download
Jun 16, 2022 at 1:42 PM CEST Genmab A/S has published its Articles of Association	Download
Jun 9, 2022 at 11:17 PM CEST Genmab Commences New Arbitration Under License Agreement With Janssen	Download
Jun 9, 2022 at 8:58 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab	Download
Jun 8, 2022 at 8:33 PM CEST Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference	Download
Jun 1, 2022 at 6:22 PM CEST Major Shareholder Announcement	Download
May 18, 2022 at 3:27 PM CEST Genmab A/S has published its Articles of Association	Download
May 17, 2022 at 8:32 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
May 11, 2022 at 5:02 PM CEST Genmab Announces Financial Results for the First Quarter of 2022	Download
Apr 19, 2022 at 12:30 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022	Download
Apr 13, 2022 at 11:25 PM CEST Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)	Download
Apr 8, 2022 at 1:45 AM CEST Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement	Download
Apr 7, 2022 at 2:03 PM CEST Genmab A/S has published its Articles of Association	Download
Mar 29, 2022 at 8:35 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Mar 29, 2022 at 8:29 PM CEST Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab	Download
Mar 29, 2022 at 3:16 PM CEST Passing of Genmab A/S’ Annual General Meeting	Download
Mar 14, 2022 at 1:48 PM CET Genmab Announces the Nomination of a New Member of the Company’s Board of Directors	Download
Mar 9, 2022 at 12:13 PM CET Genmab A/S has published its Articles of Association
Mar 1, 2022 at 3:14 PM CET Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer	Download

NEWS & EVENTS

Through timely company announcements, media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year.

Genmab News

Genmab News

Who we are

Turning insights into medicine

Innovation for the future

Genmab A/S

Genmab B.V.

Genmab US, Inc.

Genmab K.K.

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.